Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21^st century approaches.

In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.

Steven Powell, chair of the board at Cambridge Cognition, talks about the group’s latest spin-off company, Monument Therapeutics.

A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.

In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.

In Vivo held its first executive briefing in December 2019 focused on the outlook for the biopharma sector in the 2020s. Looking to the next decade, six panelists debated in front of an audience of invited guests a variety of issues expected to dominate agendas: pricing and reimbursement, digital transformation, mergers and acquisitions, funding and more.